BACKGROUND: Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in @entity1 with @entity2023 but has not previously been investigated in @entity1 with perennial symptoms. OBJECTIVE: To investigate the efficacy, safety, and tolerability of omalizumab in the treatment of @entity9590 ( @entity9590 ). METHODS: Two hundred eighty-nine @entity1 (aged 12 to 70 years) with moderate-to-severe symptomatic @entity9590 were randomized to 16 weeks' double-blind subcutaneous treatment with either placebo (n = 145) or omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks; n = 144). The primary efficacy variable was the mean daily nasal severity score, as determined from @entity1 daily diary cards. Secondary efficacy variables included use of rescue @entity16206 , @entity7370 -specific quality of life (RQoL), and @entity1 ' evaluation of treatment efficacy. Safety and tolerability were evaluated from adverse event reports and laboratory safety parameters. RESULTS: Throughout 16 weeks of treatment, the mean daily nasal severity score was significantly lower in omalizumab-treated @entity1 than with placebo (P < 0.001). The improvement in symptoms when taking omalizumab was paralleled by a reduction in use of rescue @entity16206 (P < or = 0.005 overall) and improved RQoL relative to placebo. @entity1 ' evaluation of treatment efficacy significantly favored omalizumab over placebo (P = 0.001). Omalizumab therapy was well tolerated. There were no safety concerns. CONCLUSIONS: Omalizumab was safe and well tolerated in the treatment of @entity1 with @entity9590 , providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity16206 :: ('CHEBI:37956', 'Chemical') :: ['antihistamine'] @entity7370 :: ('OMIM:613207', 'Disease') :: ['rhinoconjunctivitis'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['seasonal allergic rhinitis'] @entity9590 :: ('MESH:D012221', 'Disease') :: ['perennial allergic rhinitis', 'PAR']
@entity9590 :: (MESH:D012221,Disease) :: ['perennial allergic rhinitis']
